First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
第一作者:
Luis,Paz-Ares
第一单位:
Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Universidad Complutense & CiberOnc, Madrid, Spain. Electronic address: lpazaresr@seom.org.
作者:
主题词
老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);无病生存(Disease-Free Survival);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);肿瘤复发, 局部(Neoplasm Recurrence, Local);肿瘤分期(Neoplasm Staging);治疗结果(Treatment Outcome)
DOI
10.1016/S1470-2045(20)30641-0
PMID
33476593
发布时间
2021-03-04
- 浏览4

The Lancet. Oncology
198-211页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文